SYNT 002

Drug Profile

SYNT 002

Alternative Names: SYNT002

Latest Information Update: 28 Mar 2017

Price : $50

At a glance

  • Originator Syntimmune
  • Class
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic disorders

Most Recent Events

  • 20 Mar 2017 Preclinical trials in Metabolic disorders in USA (unspecified route) before March 2017
  • 20 Mar 2017 Syntimmune plans IND-enabling trials for SYNT 002 in 2017
  • 20 Mar 2017 Pharmacodynamics data from a preclinical trial in Metabolic disorders released by Syntimmune
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top